Additional file 7. Search strategies for cost-effectiveness of SGLT2is versus DPP4is

We searched for articles with available full text published in English from PubMed and Embase from the inception of each database to July 2, 2021, that reported a cost-effectiveness analysis of sodium-glucose cotransporter-2 inhibitors (SGLT2is) versus dipeptidyl peptidase 4 inhibitors (DPP4is). The search strategies, which used the framework Patient Intervention Comparison Outcome (PICO), and keywords are listed in the following table. 14 and 12 articles were identified from PubMed and Embase, respectively.

Search strategies for literature review in framework Patient Intervention Comparison Outcome (PICO)

#	Keywords
	Patient
1	Type 2 diabetes
	Intervention
2	Sodium glucose cotransporter 2 inhibitor
3	SGLT2 inhibitor
4	SGLT2i
5	Empagliflozin
6	Dapagliflozin
7	Canagliflozin
8	Ertugliflozin
9	Ipragliflozin
10	Luseogliflozin
11	Remogliflozin
12	Sergliflozin
13	Sotagliflozin
14	Tofogliflozin
	Comparison
15	Dipeptidyl peptidase 4 inhibitor
16	DPP4 inhibitor
17	DPP4i
18	Sitagliptin
19	Saxagliptin
20	Vildagliptin
21	Linagliptin
22	Alogliptin
23	Gemigliptin

24 Anagliptin
25 Teneligliptin
26 Trelagliptin
27 Omarigliptin
28 Evogliptin
29 Gosogliptin

Outcome

30 Cost-effectiveness
31 Economic
32 Cost-utility

Search strategy: 1 AND (2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14) AND (15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29) AND (30 OR 31 OR 32)